A323990 Stock Overview
Develops and sells cancer immune cell therapy products in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vaxcell-Bio Therapeutics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩14,180.00 |
| 52 Week High | ₩47,416.67 |
| 52 Week Low | ₩13,010.00 |
| Beta | 3.6 |
| 11 Month Change | 3.73% |
| 3 Month Change | -16.78% |
| 1 Year Change | -59.44% |
| 33 Year Change | -77.81% |
| 5 Year Change | n/a |
| Change since IPO | 59.77% |
Recent News & Updates
We Think Vaxcell-Bio Therapeutics (KOSDAQ:323990) Can Afford To Drive Business Growth
Jul 29
We're Interested To See How Vaxcell-Bio Therapeutics (KOSDAQ:323990) Uses Its Cash Hoard To Grow
Apr 01Shareholder Returns
| A323990 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -5.5% | -1.3% | -1.0% |
| 1Y | -59.4% | 35.1% | -0.1% |
Return vs Industry: A323990 underperformed the KR Biotechs industry which returned 35.1% over the past year.
Return vs Market: A323990 underperformed the KR Market which returned -0.1% over the past year.
Price Volatility
| A323990 volatility | |
|---|---|
| A323990 Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A323990's share price has been volatile over the past 3 months.
Volatility Over Time: A323990's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | n/a | www.vaxcell-bio.com |
Vaxcell-Bio Therapeutics Co., Ltd. develops and sells cancer immune cell therapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea.
Vaxcell-Bio Therapeutics Co., Ltd. Fundamentals Summary
| A323990 fundamental statistics | |
|---|---|
| Market cap | ₩326.04b |
| Earnings (TTM) | -₩10.43b |
| Revenue (TTM) | ₩69.60m |
4,685x
P/S Ratio-31.3x
P/E RatioIs A323990 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A323990 income statement (TTM) | |
|---|---|
| Revenue | ₩69.60m |
| Cost of Revenue | ₩35.33m |
| Gross Profit | ₩34.27m |
| Other Expenses | ₩10.47b |
| Earnings | -₩10.43b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -453.72 |
| Gross Margin | 49.24% |
| Net Profit Margin | -14,989.18% |
| Debt/Equity Ratio | 0% |
How did A323990 perform over the long term?
See historical performance and comparison